WEKO3
アイテム
{"_buckets": {"deposit": "5483fe60-9f96-41b5-9bf7-88ec1db2789f"}, "_deposit": {"created_by": 6, "id": "26907", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26907"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026907", "sets": ["9"]}, "author_link": ["119647", "119653", "119654", "119646", "119652", "119655", "119657", "119658", "119650", "119643", "119660", "119645", "119642", "119641", "119649", "119644", "119651", "119659", "119656", "119648"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-09-17", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "18", "bibliographicPageStart": "4221", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "Journal of Clinical Medicine"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, p = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy. ", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of Clinical Medicine, 10(18), art. no. 4221; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/jcm10184221", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2077-0383", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Dotsu, Yosuke"}], "nameIdentifiers": [{"nameIdentifier": "119641", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "119642", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukuda, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "119643", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suyama, Takayuki"}], "nameIdentifiers": [{"nameIdentifier": "119644", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Honda, Noritaka"}], "nameIdentifiers": [{"nameIdentifier": "119645", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Umeyama, Yasuhiro"}], "nameIdentifiers": [{"nameIdentifier": "119646", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taniguchi, Hirokazu"}], "nameIdentifiers": [{"nameIdentifier": "119647", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Gyotoku, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "119648", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takemoto, Shinnosuke"}], "nameIdentifiers": [{"nameIdentifier": "119649", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tagawa, Ryuta"}], "nameIdentifiers": [{"nameIdentifier": "119650", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogata, Ryosuke"}], "nameIdentifiers": [{"nameIdentifier": "119651", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomono, Hiromi"}], "nameIdentifiers": [{"nameIdentifier": "119652", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimada, Midori"}], "nameIdentifiers": [{"nameIdentifier": "119653", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Senju, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "119654", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakatomi, Katsumi"}], "nameIdentifiers": [{"nameIdentifier": "119655", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagashima, Seiji"}], "nameIdentifiers": [{"nameIdentifier": "119656", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soda, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "119657", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "119658", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ashizawa, Kazuto"}], "nameIdentifiers": [{"nameIdentifier": "119659", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mukae, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "119660", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-12-02"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JCM10_4221.pdf", "filesize": [{"value": "1.6 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 1600000.0, "url": {"label": "JCM10_4221.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26907/files/JCM10_4221.pdf"}, "version_id": "a790027f-3dfe-4824-b1aa-f6b49f3c8f4f"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "amrubicin", "subitem_subject_scheme": "Other"}, {"subitem_subject": "chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "granulocyte colony-stimulating factor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "febrile neutropenia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "lung cancer", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor"}]}, "item_type_id": "2", "owner": "6", "path": ["9"], "permalink_uri": "http://hdl.handle.net/10069/00041073", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-02"}, "publish_date": "2021-12-02", "publish_status": "0", "recid": "26907", "relation": {}, "relation_version_is_last": true, "title": ["Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor"], "weko_shared_id": -1}
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
http://hdl.handle.net/10069/00041073
http://hdl.handle.net/10069/000410731ec2bf73-88ab-4700-b357-ce0f90220bb2
名前 / ファイル | ライセンス | アクション |
---|---|---|
JCM10_4221.pdf (1.6 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-02 | |||||
タイトル | ||||||
タイトル | Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | amrubicin | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | chemotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | granulocyte colony-stimulating factor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | febrile neutropenia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | lung cancer | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Dotsu, Yosuke
× Dotsu, Yosuke× Yamaguchi, Hiroyuki× Fukuda, Minoru× Suyama, Takayuki× Honda, Noritaka× Umeyama, Yasuhiro× Taniguchi, Hirokazu× Gyotoku, Hiroshi× Takemoto, Shinnosuke× Tagawa, Ryuta× Ogata, Ryosuke× Tomono, Hiromi× Shimada, Midori× Senju, Hiroaki× Nakatomi, Katsumi× Nagashima, Seiji× Soda, Hiroshi× Ikeda, Hiroaki× Ashizawa, Kazuto× Mukae, Hiroshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3-): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. Prophylactic PEG-G-CSF was not used in cycle 1 in any case. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, p = 0.025). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy. | |||||
書誌情報 |
Journal of Clinical Medicine 巻 10, 号 18, p. 4221, 発行日 2021-09-17 |
|||||
出版者 | ||||||
出版者 | MDPI | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2077-0383 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/jcm10184221 | |||||
権利 | ||||||
権利情報 | © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of Clinical Medicine, 10(18), art. no. 4221; 2021 |